New cocktail of immune drugs shows promise for tough prostate cancer
NCT ID NCT03493945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to four drugs together in 2-week cycles, and treatment continued until the cancer worsened or side effects became too severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can your own immune cells beat advanced cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?